INCB177054 / Incyte - LARVOL DELTA

Pharmacodynamic profiling of diacylglycerol kinase inhibition reveals immune activation and synergy with PD1 blockade in preclinical tumor models (SITC 2025) - P1/2 | "These findings support the immunostimulatory potential of DGK inhibition and the rationale for clinical evaluation. A phase 1/2 study of INCB177054 in select tumors (NCT06873789) is underway."

IO biomarker • PK/PD data • Preclinical • Oncology • CD8 • ENTPD1 • HAVCR2 • PTPRC • TNFA

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=9 | Active, not recruiting | Sponsor: Incyte Corporation | Recruiting ➔ Active, not recruiting | N=322 ➔ 9

Enrollment change • Enrollment closed • Solid Tumor

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=322 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

INCB177054: A novel, potent, orally bioavailable DGKα/ζ dual inhibitor enhances T-cell function and demonstrates potent antitumor activity (AACR 2025) - "In addition, those mice were protected against a rechallenge with the same tumor, suggesting generation of antitumor T-cell memory. Collectively, our data indicate INCB177054 is a potent and selective DGKα/ζ dual inhibitor that enhances T-cell activity and induces significant tumor growth inhibition when combined with anti-PD(L)-1, suggesting this potential therapy might increase responses to checkpoint inhibitor treatment in patients with cancer."

IO biomarker • Oncology • CD69 • IFNG • IL2

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 (Businesswire) - "Incyte...announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30."

Clinical data • Preclinical • Myelofibrosis • Myeloproliferative Neoplasm • Ovarian Cancer